NASDAQ · DSGN
Design Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DSGN: Nov 4, 2026
Design Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.38 | $-0.36 | $-0.39 | 2 |
| Dec 2026 | $-0.50 | $-0.39 | $-0.62 | 2 |
| Mar 2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Jun 2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · RTTNews · Fintel- Zacks · Jun 9, 9:40 AM EDTAre Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
- Zacks · May 27, 9:58 AM EDTFDA Extends Review Time for AZN's Camizestrant Combo in Breast CancerAstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
- Zacks · May 25, 11:30 AM EDTAZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast CancerAstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.
- BNK Invest · May 19, 3:19 PM EDTNotable Tuesday Option Activity: AEVA, RKLB, DSGNAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Aeva Technologies Inc (Symbol: AEVA), where a total of 12,218 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to abo
- RTTNews · May 18, 8:07 AM EDTDesign Therapeutics Posts Four-Week RESTORE-FA Gains In Friedreich Ataxia; Stock Up(RTTNews) – Design Therapeutics, Inc. (DSGN) reported that its GeneTAC candidate DT-216P2 delivered dose-dependent improvements in both biomarkers and clinical measures in patients with Friedreich ataxia after four weeks of intravenous dosing in the ongoing Phase 1/2 RESTORE-FA t
- RTTNews · May 18, 1:54 AM EDTDesign Therapeutics To Present RESTORE-FA Trial Data Today; Stock Up(RTTNews) – Design Therapeutics, Inc. (DSGN), will host an investor webcast today, May 18,2026, to review data from its RESTORE-FA clinical trial evaluating DT-216P2 in patients with Friedreich's ataxia.
- Fintel · May 14, 4:23 AM EDTDesign Therapeutics (DSGN) Price Target Increased by 17.05% to 17.51The average one-year price target for Design Therapeutics (NasdaqGS:DSGN) has been revised to $17.51 / share. This is an increase of 17.05% from the prior estimate of $14.96 dated April 25, 2026. The price target is an average of many targets provided by analy
- Zacks · May 11, 12:00 PM EDTDesign Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should KnowDoes Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- RTTNews · Apr 29, 2:31 AM EDTDesign Therapeutics Q1 Net Loss Narrows; Expects To Update On RESTORE-FA Trial In H2,2026(RTTNews) – Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company, reported first-quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC portfolio.
- Fintel · Mar 27, 12:59 AM EDTDesign Therapeutics (DSGN) Price Target Increased by 12.82% to 14.96The average one-year price target for Design Therapeutics (NasdaqGS:DSGN) has been revised to $14.96 / share. This is an increase of 12.82% from the prior estimate of $13.26 dated February 21, 2026. The price target is an average of many targets provided by an
- Fintel · Mar 16, 8:03 PM EDTJefferies Initiates Coverage of Design Therapeutics (DSGN) with Buy RecommendationFintel reports that on March 16, 2026, Jefferies initiated coverage of Design Therapeutics (NasdaqGS:DSGN) with a Buy recommendation. Analyst Price Forecast Suggests 20.66% Upside
- Fintel · Jan 13, 7:25 PM ESTDesign Therapeutics (DSGN) Price Target Increased by 10.64% to 13.26The average one-year price target for Design Therapeutics (NasdaqGS:DSGN) has been revised to $13.26 / share. This is an increase of 10.64% from the prior estimate of $11.98 dated December 18, 2025. The price target is an average of many targets provided by an
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Design Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.